Femara tablets are a non-steroidal antitumor drug, a specific inhibitor of the aromatase enzyme. The mechanism of action of Femara is based on inhibiting the growth of tumor cells by binding to the subunit of the aromatase enzyme, which takes part in the synthesis of estrogens that stimulate the development of cancer cells. According to the description, the drug is recommended for use in the initial form of breast cancer during the postmenopausal period, as well as for patients with a common type of breast cancer in the postmenopausal period that have been treated with anti-estrogens (Tamoxifen).
Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents
Femara is a non-steroidal anticancer therapeutic agent that is widely used in the current-day paradigm of the therapy of breast cancer. Being a highly specific inhibitor the medication blocks the synthesis of the enzyme aromatase, which is responsible for the production of the most part of estrogen in women in postmenstrual age. Because this chemical substance plays one of the main roles in the growth of breast tumors, taking the drug that prevents its release, allows achieving satisfying results at the different phases of the adjuvant hormonal anticancer therapy.
In addition, the current medical paradigm gives encouragement to the use of the medicine for the healing of women after the end of the five-year-treatment with Tamoxifen (or some of its derivatives). In the parlance of the available statistical data, taking this drug under these conditions have a statistically correlated favorable effect.
How to take
The exact scheme should be suggested by your therapists. Usually, the medication is taken once per day. Meticulous adherence to the provided regimen is a key to successful therapy devoid of possible negative outcomes.
- The duration of the course of therapy should be determined only by your physician inasmuch as it varies greatly in different groups of patients.
- You should not discontinue the therapy or change the dosage without the doctor’s permission.
- The drug may be taken with and without food, regardless of the diet, but at the same time of day to the extent reasonably practical.
- Do NOT try to compensate for the missed dose.
- If you have missed several doses in a row, you should seek your physician’s advice. If you forgot about it only one time, you may ignore this incident and continue taking the drug as prescribed.
The target group of patients who should receive the pills on a regular basis is rather narrow: the drug is intended for use mostly in women who reached the postmenopausal period. Taking it by other patients or using it without prescription is strictly forbidden due to the potentially unfavorable effects.
The medication may increase the level of cholesterol in the blood. When using the drug you may need to monitor this parameter.
Allergic reactions of any severity to the substances that are included in the composition of this therapeutic agent sufficiently attest to the cancellation of the treatment.
The active ingredients of the pharmacological agent may reduce the metabolic pathways of calcium and decrease the density of the bone tissues, which is especially important for women of postmenstrual age.
The number of adverse reactions that may be expected because of the medical maintenance is not great. Nevertheless, you must regard all of the symptoms with due attention. In rare cases, the therapeutic agent may cause increased sweating, nausea, changes of peripheral vision, chest pain, depression, or vaginal bleeding.
The decreased bone strength that may be caused by the treatment may result in various fractures. If you already have osteoporosis avoid increased physical activity throughout the entire course of therapy and periodically check your condition in order to prevent all hypothetical risks for your health.
Hypersensitivity to the compounds present in the therapeutic agent is very rare and may be registered in less than 0.01% of patients.